Steven Deitcher, M.D., FSM ’86, FSM ’88

Founder, CEO, and Chairman, Bespoke Biotherapeutics

I am the Founder, CEO, and Chairman of Bespoke Biotherapeutics, developing genome‑engineered B‑cell therapeutics for hemophilia A and HER2+ breast cancer, and co‑founder of a stealth clinical‑stage brain‑regeneration company. I previously held executive roles at Radimmune, Medeor, Talon, where I led Marqibo® from IND to FDA accelerated approval and acquisition, and Nuvelo. Earlier, I served as Chief of Hematology and Coagulation Medicine at the Cleveland Clinic. A Northwestern HPME graduate, I trained at Barnes/Washington University and completed hematology/oncology fellowships and post‑doctoral work at Tufts.

My greater than 15 years of private and public company C-suite product development and commercialization know-how spans cell therapies, radioimmunotherapies, protein therapeutics, aptamers, and nanoparticle-targeted small molecules in the regenerative medicine, oncology, hematology, organ transplantation and cardiovascular therapeutic spaces.